JP7692546B1 - ウラシル誘導体の製造方法 - Google Patents

ウラシル誘導体の製造方法 Download PDF

Info

Publication number
JP7692546B1
JP7692546B1 JP2025523061A JP2025523061A JP7692546B1 JP 7692546 B1 JP7692546 B1 JP 7692546B1 JP 2025523061 A JP2025523061 A JP 2025523061A JP 2025523061 A JP2025523061 A JP 2025523061A JP 7692546 B1 JP7692546 B1 JP 7692546B1
Authority
JP
Japan
Prior art keywords
formula
compound
compound represented
salt
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2025523061A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2025018428A1 (https=
Inventor
陽一 平野
直登 佐原
勝也 山川
ティーン レー，フック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of JPWO2025018428A1 publication Critical patent/JPWO2025018428A1/ja
Priority to JP2025070749A priority Critical patent/JP2025114610A/ja
Application granted granted Critical
Publication of JP7692546B1 publication Critical patent/JP7692546B1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2025523061A 2023-10-05 2024-10-04 ウラシル誘導体の製造方法 Active JP7692546B1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025070749A JP2025114610A (ja) 2023-10-05 2025-04-22 ウラシル誘導体の製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023173427 2023-10-05
JP2023173427 2023-10-05
PCT/JP2024/035562 WO2025018428A2 (ja) 2023-10-05 2024-10-04 ウラシル誘導体の製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025070749A Division JP2025114610A (ja) 2023-10-05 2025-04-22 ウラシル誘導体の製造方法

Publications (2)

Publication Number Publication Date
JPWO2025018428A1 JPWO2025018428A1 (https=) 2025-01-23
JP7692546B1 true JP7692546B1 (ja) 2025-06-13

Family

ID=94282311

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2025523061A Active JP7692546B1 (ja) 2023-10-05 2024-10-04 ウラシル誘導体の製造方法
JP2025070749A Pending JP2025114610A (ja) 2023-10-05 2025-04-22 ウラシル誘導体の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025070749A Pending JP2025114610A (ja) 2023-10-05 2025-04-22 ウラシル誘導体の製造方法

Country Status (2)

Country Link
JP (2) JP7692546B1 (https=)
WO (1) WO2025018428A2 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61218569A (ja) * 1985-03-01 1986-09-29 デユフアル・インテルナチオナル・レセールフ・ベー・ヴエー 抗腫瘍活性を有するベンゾイルウレア誘導体及びその製造法及び該誘導体を活性物質とする抗腫瘍剤
CN115368290A (zh) * 2022-07-12 2022-11-22 湖南工业大学 一种植物生长调节剂及其制备方法
WO2023195529A1 (ja) * 2022-04-08 2023-10-12 塩野義製薬株式会社 ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物
CN117658932A (zh) * 2023-12-01 2024-03-08 郑州大学 一种含酰胺结构单元的氨基二硫代酯衍生物及其制备方法和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61218569A (ja) * 1985-03-01 1986-09-29 デユフアル・インテルナチオナル・レセールフ・ベー・ヴエー 抗腫瘍活性を有するベンゾイルウレア誘導体及びその製造法及び該誘導体を活性物質とする抗腫瘍剤
WO2023195529A1 (ja) * 2022-04-08 2023-10-12 塩野義製薬株式会社 ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物
WO2023195530A1 (ja) * 2022-04-08 2023-10-12 塩野義製薬株式会社 ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物
CN115368290A (zh) * 2022-07-12 2022-11-22 湖南工业大学 一种植物生长调节剂及其制备方法
CN117658932A (zh) * 2023-12-01 2024-03-08 郑州大学 一种含酰胺结构单元的氨基二硫代酯衍生物及其制备方法和应用

Also Published As

Publication number Publication date
JPWO2025018428A1 (https=) 2025-01-23
WO2025018428A2 (ja) 2025-01-23
JP2025114610A (ja) 2025-08-05
WO2025018428A3 (ja) 2025-03-13

Similar Documents

Publication Publication Date Title
TWI815396B (zh) 具有病毒增殖抑制作用之三嗪衍生物及含有其等之醫藥組合物
JP7624093B2 (ja) ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物
TW202320793A (zh) 含有三嗪衍生物之醫藥組合物
JP2024178473A (ja) ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
JP7261529B1 (ja) ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法
JP7692546B1 (ja) ウラシル誘導体の製造方法
JP7674711B1 (ja) ウラシル誘導体を含有する医薬組成物
RU2806042C1 (ru) Триазиновые производные, имеющие ингибиторную активность в отношении репликации вируса, и содержащая их фармацевтическая композиция
BR112022023272B1 (pt) Derivados de triazina tendo efeito inibidor de propagação de vírus e cocristal do mesmo com ácido fumárico
BR122023002208B1 (pt) Composições farmacêuticas compreendendo derivados de triazina para o tratamento e/ou prevenção de covid-19
BR122023002208A2 (pt) Composições farmacêuticas compreendendo derivados de triazina tendo efeito inibidor de propagação de vírus, inibidores e usos
HK40081541A (en) Triazine derivative having virus propagation inhibitory effect, and pharmaceutical composition containing same
HK40081541B (zh) 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250422

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250603

R150 Certificate of patent or registration of utility model

Ref document number: 7692546

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150